Aamena Jabeen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aamena Jabeen has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Eltaib Elmobark
Department of Pharmaceutics, College of Pharmacy, Jazan University
5 shared publications - Sivakumar Sivagurunathan Moni
Department of Pharmaceutics, College of Pharmacy, Jazan University
5 shared publications - Ahmad Salawi
Department of Pharmaceutics, College of Pharmacy, Jazan University
3 shared publications - Fatma Ayish
Internal Medicine Department, Faculty of Medicine, Jazan University
2 shared publications - Mawada Abubaker Abdelgadir Mohammed
Clinical Practice Department, College of Pharmacy, Jazan University
2 shared publications - Muhammad Hadi Sultan
Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Taylor & Francis in All Life
- Vol. 19 (1)
Honey as a functional food and nutraceutical: bioactive properties, health benefits, and pharmaceutical perspectives
Honey, a natural product with a long medicinal tradition, is valued for its therapeutic potential in treating numerous physiological dysfunctions (Larsen and Ahmed 2022). The composition of honey v...
- 4 September 2026
- Published by Taylor & Francis in All Life
- Vol. 19 (1)
Open AccessHoney as a functional food and nutraceutical: bioactive properties, health benefits, and pharmaceutical perspectives
Honey, a natural product with a long medicinal tradition, is valued for its therapeutic potential in treating numerous physiological dysfunctions (Larsen and Ahmed 2022). The composition of honey v...
- Open Access
- 28 July 2026
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 27 (1) , 2708386
Molecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics
1. Insulin resistance (IR) is a primary metabolic disorder characterized by decreased sensitivity of cells to insulin, leading to overproduction of insulin (hyperinsulinemia) and a multitude of met...
- 28 July 2026
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 27 (1) , 2708386
Open AccessMolecular interplay of insulin resistance and cancer: advances in monoclonal antibody therapeutics
1. Insulin resistance (IR) is a primary metabolic disorder characterized by decreased sensitivity of cells to insulin, leading to overproduction of insulin (hyperinsulinemia) and a multitude of met...
- Open Access
- 30 April 2026
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 34 (2)
Targeting Neurovascular Pathways: Gene Therapy as a Novel Treatment for Vascular Dementia After Stroke
Stroke is the second leading cause of mortality worldwide, resulting from an interruption of blood flow to the brain, which subsequently diminishes oxygen supply. Although strokes can occur at any age, incidence rises significantly after 55. Vascular dementia, a progressive condition associated with cerebral infarction, is a long-term sequela of stroke that predominantly affects older populations. To date, there is no cure for this form of dementia. Recent experimental studies in rodent models, however, demonstrate promising outcomes in combating neuronal degeneration through gene treatments utilizing brain-derived neurotrophic factor, fibroblast growth factor-2, and vascular endothelial growth factor. These advancements suggest a potential breakthrough in vascular dementia treatment. This comprehensive review delves into the complexities of strokes, exploring their challenges and constraints. Furthermore, we explore the growing field of gene therapy, highlighting successful interventions that may revolutionize the landscape of vascular dementia treatment. This review aims to provide a refined understanding of stroke-related issues and the transformative potential of gene-based interventions in mitigating the burden of vascular dementia.
- 30 April 2026
- Published by Springer Nature in Saudi Pharmaceutical Journal
- Vol. 34 (2)
Open AccessTargeting Neurovascular Pathways: Gene Therapy as a Novel Treatment for Vascular Dementia After Stroke
Stroke is the second leading cause of mortality worldwide, resulting from an interruption of blood flow to the brain, which subsequently diminishes oxygen supply. Although strokes can occur at any age, incidence rises significantly after 55. Vascular dementia, a progressive condition associated with cerebral infarction, is a long-term sequela of stroke that predominantly affects older populations. To date, there is no cure for this form of dementia. Recent experimental studies in rodent models, however, demonstrate promising outcomes in combating neuronal degeneration through gene treatments utilizing brain-derived neurotrophic factor, fibroblast growth factor-2, and vascular endothelial growth factor. These advancements suggest a potential breakthrough in vascular dementia treatment. This comprehensive review delves into the complexities of strokes, exploring their challenges and constraints. Furthermore, we explore the growing field of gene therapy, highlighting successful interventions that may revolutionize the landscape of vascular dementia treatment. This review aims to provide a refined understanding of stroke-related issues and the transformative potential of gene-based interventions in mitigating the burden of vascular dementia.
- Open Access
- 14 November 2025
- Published by Taylor & Francis in Critical Public Health
- Vol. 35 (1)
Beyond pain relief: a comprehensive review of analgesic self-medication and its broad implications
- 14 November 2025
- Published by Taylor & Francis in Critical Public Health
- Vol. 35 (1)
Open AccessBeyond pain relief: a comprehensive review of analgesic self-medication and its broad implications
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 83, e244479
Spectral analysis, in vitro cytotoxicity and antibacterial studies of bioactive principles from the leaves of Conocarpus lancifolius, a common tree of Jazan, Saudi Arabia
The objective of the present study was to analyse the bioactive compounds of the leaves of Conocarpus lancifolius (C. lancifolius). The GC-MS analysis of the hot methanolic extract of the leaves (HMEL) of C. lancifolius exhibited the bioactive compounds such as 1-(3-Methoxy-2-nitrobenzyl) iso quinoline, morphin-4-ol-6,7-dione, 1-bromo-N-methyl-, phytol, hexadecanoic acid, 2,3-dihydroxypropyl ester, 2,2':4',2”-terthiophene, ethyl iso-allocholate, caryophyllene oxide, campesterol, epiglobulol, cholestan-3-ol, 2-methylene-, (3á,5à)-, dasycarpidan-1-methanol, acetate (ester) and oleic acid, eicosyl ester. The FT-IR analysis of HMEL of C. lancifolius showed a unique peak at 3184, 2413, 1657 cm-1 representing coumaric acid, chlorogenic acid and ferulic acid. The HMEL of C. lancifolius was actively inhibiting the proliferation of breast cancer cells MCF-7 ATCC at the concentration of 72.66 ± 8.21 µg/ml as IC50 value. The HMEL of C. lancifolius also revealed a good spectrum of activity against Gram-positive and Gram-negative bacterial cultures screened in this work. The activity observed has shown more or less similar effects against screened bacteria. However, the magnitude of potentiality was significantly lesser compared to standard ciprofloxacin disc at p< 0.001 level (99% confidence intervals). Furthermore, the study demonstrating the bioactive compounds can be isolated from the leaves of C. lancifolius.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 83, e244479
Open AccessSpectral analysis, in vitro cytotoxicity and antibacterial studies of bioactive principles from the leaves of Conocarpus lancifolius, a common tree of Jazan, Saudi Arabia
The objective of the present study was to analyse the bioactive compounds of the leaves of Conocarpus lancifolius (C. lancifolius). The GC-MS analysis of the hot methanolic extract of the leaves (HMEL) of C. lancifolius exhibited the bioactive compounds such as 1-(3-Methoxy-2-nitrobenzyl) iso quinoline, morphin-4-ol-6,7-dione, 1-bromo-N-methyl-, phytol, hexadecanoic acid, 2,3-dihydroxypropyl ester, 2,2':4',2”-terthiophene, ethyl iso-allocholate, caryophyllene oxide, campesterol, epiglobulol, cholestan-3-ol, 2-methylene-, (3á,5à)-, dasycarpidan-1-methanol, acetate (ester) and oleic acid, eicosyl ester. The FT-IR analysis of HMEL of C. lancifolius showed a unique peak at 3184, 2413, 1657 cm-1 representing coumaric acid, chlorogenic acid and ferulic acid. The HMEL of C. lancifolius was actively inhibiting the proliferation of breast cancer cells MCF-7 ATCC at the concentration of 72.66 ± 8.21 µg/ml as IC50 value. The HMEL of C. lancifolius also revealed a good spectrum of activity against Gram-positive and Gram-negative bacterial cultures screened in this work. The activity observed has shown more or less similar effects against screened bacteria. However, the magnitude of potentiality was significantly lesser compared to standard ciprofloxacin disc at p< 0.001 level (99% confidence intervals). Furthermore, the study demonstrating the bioactive compounds can be isolated from the leaves of C. lancifolius.
- Open Access
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 82, e256158
Wound-healing and cytokine-modulating potential of medicinal oil formulation comprising leaf extract of Murraya koenigii and olive oil
The study investigated the wound healing effect of medicinal oil (MO) formulation prepared from Murraya koenigii leaves extract (methanolic) incorporated in olive oil. The MO was visually transparent, homogenous, smooth in texture, the viscosity grade was observed as 140 cP and easily spreadable. Pro-inflammatory cytokines IL-1β, IL-6, and TNF-α were significantly reduced to 82.3 ± 3.5, 156 ± 6.2, 137.3. ± 5.5 pg/ml, respectively after treatment with MO when compared to disease control animals that showed IL-1β, IL-6, and TNF-α levels of 170 ± 6, 265 ± 7, and 288.6 ± 11, pg/ml respectively. The level of pro-inflammatory cytokine in povidone iodine solution (PIS) group was 95.3 ± 3, 162 ± 6, 177.6 ± 8.9 pg/ml of IL-1β, IL-6, and TNF-α respectively. Interestingly, the wound-healing efficacy of MO was found better as compared to povidone iodine treated standard group and concluded that MO has excellent wound healing effect.
- 1 January 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Biology
- Vol. 82, e256158
Open AccessWound-healing and cytokine-modulating potential of medicinal oil formulation comprising leaf extract of Murraya koenigii and olive oil
The study investigated the wound healing effect of medicinal oil (MO) formulation prepared from Murraya koenigii leaves extract (methanolic) incorporated in olive oil. The MO was visually transparent, homogenous, smooth in texture, the viscosity grade was observed as 140 cP and easily spreadable. Pro-inflammatory cytokines IL-1β, IL-6, and TNF-α were significantly reduced to 82.3 ± 3.5, 156 ± 6.2, 137.3. ± 5.5 pg/ml, respectively after treatment with MO when compared to disease control animals that showed IL-1β, IL-6, and TNF-α levels of 170 ± 6, 265 ± 7, and 288.6 ± 11, pg/ml respectively. The level of pro-inflammatory cytokine in povidone iodine solution (PIS) group was 95.3 ± 3, 162 ± 6, 177.6 ± 8.9 pg/ml of IL-1β, IL-6, and TNF-α respectively. Interestingly, the wound-healing efficacy of MO was found better as compared to povidone iodine treated standard group and concluded that MO has excellent wound healing effect.